Sickle Cell Clinical Research and Intervention Program
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02098863|
Recruitment Status : Recruiting
First Posted : March 28, 2014
Last Update Posted : August 7, 2019
Despite the important work of previous sickle cell disease (SCD) cohort studies, there remain many understudied areas that require investigation. An important knowledge deficit is the slow but progressive process of chronic end-organ dysfunction. The majority of organ dysfunction becomes apparent in the young adult years, but comprehensive assessment of adults and understanding of predictors of adulthood organ dysfunction are insufficient. Similarly, the role of disease-modifying therapies, such as hydroxyurea, in preventing organ dysfunction later in life is not clear. Extended follow-up of patients through the transition into adulthood is imperative to understand the long-term implications of pediatric sickle cell care.
This observational study will collect data in a systematic fashion at participants' regular clinic visits to answer the objectives described below.
In addition to primary study objectives, SCCRIP participants will be eligible to participate in a sub-study, which will investigate genetically determined responses to Hydroxyurea (HU) via a pharmacokinetic study (PK). This one time study will involve blood collection at timed intervals proceeding a dose of HU. Defining the basis for this inter-individual variability will allow the identification of poor HU responders prior to initiation of therapy and the seeking of alternative treatments which seek to optimize disease treatment by accounting for individual variability in genes, environment, and lifestyle.
|Condition or disease|
|Sickle Cell Disease|
Hide Detailed Description
The St. Jude Pediatric SCD Program has developed a comprehensive plan of care that spans the ages of 0 to 25, and provides the structure for screening and monitoring disease progression and complications in infancy, childhood, and young adulthood. From age 0 to 18, SCD patients are followed at St. Jude Children's Research Hospital. At age 18, their care is typically transferred to either the Methodist Adult Comprehensive Sickle Cell Disease Center in Memphis, TN, or the Regional One Health, Diggs-Kraus Sickle Cell Center in Memphis, TN, where they are routinely followed from age 18 to 25 years. After age 25, participants will be followed and invited to return to St. Jude every 6 years for study related tests until participants elect to come off study or until death.
St. Jude Children's Research Hospital and the Methodist Adult Comprehensive Sickle Cell Disease Center, in Memphis, TN serve as enrolling centers for the SCCRIP protocol.Three St. Jude Affiliate locations will also be sites of enrollment for this protocol for patients age 0 to 18 years. These include St. Jude Affiliate sites located in: Baton Rouge, Louisiana; Peoria, Illinois; and Charlotte, North Carolina. Approximately 500 additional participants are expected to be enrolled from these affiliate sites. This protocol will collect data on SCD participants from birth to end of life.
The SCD plan of care provides the specific sequence of laboratory and imaging studies that are performed according to the patient's age and expected course of illness. The following health outcomes are systematically monitored in patients with SCD: hematologic indices, pulmonary function, cardiac function, renal function, cognitive function, cerebral vasculopathy, vitamin D deficiency and bone health, parvovirus B19 immune status, ophthalmologic status, and splenic function. These tests are used to direct the patient's clinical management and initiate therapies when necessary.
In this study, the results of these tests will be collected and entered into the study database, providing longitudinal data that will inform health outcomes research regarding SCD and how the course is altered by disease-modifying therapy, in addition to facilitating future interventional projects.
- To establish a longitudinal clinical cohort of patients with sickle cell disease (SCD) to serve as a research resource to facilitate evaluation of health outcomes in SCD from pediatric care into adulthood.
- To facilitate the collection of biological samples from patients with SCD to be used in future studies investigating genetic and epigenetic contributions to disease severity, response to treatment, and morbidity and mortality.
- To determine the incidence, prevalence, and severity of SCD complications and adverse health conditions within the SCD cohort during five stages of development and adulthood: the newborn period (birth to 6 months), the infant/pre-school stage (ages 6 months to 6 years), the early school stage (ages 6 to 12 years), the adolescent stage (ages 12 to 18 years), and adulthood (ages 18 and above).
- To identify and evaluate risk factors for premature mortality and long-term morbidity in patients with SCD, including those related to disease-modifying therapies, end-organ damage, genetics, neurocognitive deficits, psychosocial factors, and behavioral causes.
- To investigate the long-term effects of hydroxyurea and other therapies on preservation of organ function, growth and development, and frequency and severity of disease complications, and their long-term medical, neurocognitive, and psychosocial toxicities.
- To determine the functional aspects of the Transition to Adult Care Program within a clinical research cohort by evaluating disease specific health literacy and readiness in relation to healthcare utilization during adult care.
- To explore the long-term alterations of prolonged antibiotic exposure on the microbial community composition among people living with SCD through the collection of swabs as guided by the Human Microbiome Project (HMP) Manual of Procedures.
Other Pre-Specified Objective:
- Define the drug-exposure to clinical response relationship of HU therapy in children with SCD.
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||10000 participants|
|Target Follow-Up Duration:||99 Years|
|Official Title:||Sickle Cell Clinical Research and Intervention Program|
|Actual Study Start Date :||April 15, 2014|
|Estimated Primary Completion Date :||December 2044|
|Estimated Study Completion Date :||December 2044|
- Relationship between treatment plan and health outcomes in participants with sickle cell disease (SCD) [ Time Frame: Every 2 years from newborn to ≤ 30 years of age, and every 6 years after age 30 until end-of-life, up until December 2044 ]As described in the Detailed Description, standard of care data will be collected from participants every two years during participants' annual clinic visits until study participation is discontinued or until participants reach death/end of life, whichever occurs last. This collection of observational data will be entered into a study database and will serve as a research resource to facilitate evaluation of health outcomes in participants with SCD from pediatric care into adulthood.
- Relationship between genetic properties of biological samples and health outcomes in participants with sickle cell disease [ Time Frame: Collected every 6 years from newborn until end-of life, up until December 2044 ]A repository of biological samples from participants with sickle cell disease will be established for future retrospective studies investigating genetic and epigenetic contributions to disease severity, response to treatment, and morbidity and mortality.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02098863
|Contact: Jane Hankins, MD, MSfirstname.lastname@example.org|
|United States, Illinois|
|Children's Hospital of Illinois at OSF-Saint Francis Medical Center||Recruiting|
|Peoria, Illinois, United States, 61637|
|Contact: Kay Saving, MD 309-624-4945|
|Principal Investigator: Kay Saving, MD|
|United States, Louisiana|
|Our Lady of the Lake Regional Medical Center||Recruiting|
|Baton Rouge, Louisiana, United States, 70808|
|Contact: Jeff Deyo, MD, PhD 225-763-6337|
|Principal Investigator: Jeff Deyo, MD, PhD|
|United States, North Carolina|
|Novant Health Hemby Children's Hospital||Recruiting|
|Charlotte, North Carolina, United States, 28204|
|Contact: Paulette Bryant, MD 704-384-1900|
|Principal Investigator: Paulette Bryant, MD|
|United States, Tennessee|
|Regional One Health, Diggs-Kraus Sickle Cell Center||Withdrawn|
|Memphis, Tennessee, United States, 38103|
|Methodist Adult Comprehensive Sickle Cell Center||Recruiting|
|Memphis, Tennessee, United States, 38104|
|Contact: Kenneth Ataga, MBBS 901-516-8182|
|Principal Investigator: Kenneth Ataga, MBBS|
|St. Jude Children's Research Hospital||Recruiting|
|Memphis, Tennessee, United States, 38105|
|Contact: Jane Hankins, MD, MS 866-278-5833 email@example.com|
|Principal Investigator: Jane Hankins, MD, MS|
|Principal Investigator:||Jane Hankins, MD, MS||St. Jude Children's Research Hospital|